Multipoint analysis of reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine turnover in the hearts of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine-induced parkinsonism

Nuclear Medicine and Biology

Volumn 36, Issue 6, 2009, Pages 623-629

  Fukumitsu, Nobuyoshi ^a   Suzuki, Masahiko ^b   Fukuda, Takahiro ^b   Kiyono, Yasushi ^c  

^a UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydroxypyridine; 125I Meta iodobenzylguanidine; Cardiac sympathetic nerves; Norepinephrine; Norepinephrine transporter; Parkinsonism

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; MOUSE; NERVE ENDING; NONHUMAN; NORADRENALIN BLOOD LEVEL; PARKINSONISM; POSTGANGLIONIC NERVE; TISSUE LEVEL; TURNOVER TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3-IODOBENZYLGUANIDINE; ANIMALS; DOPAMINE; MICE; MYOCARDIUM; NEOSTRIATUM; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PARKINSON DISEASE; TIME FACTORS; TYROSINE;

EID: 67651165190     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.04.001     Document Type: Article

References (38)

1. Wieland D.M., Brown L.E., Rogers W.L., Worthington K.C., Wu J.L., Clinthorne N.H., et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 22 (1981) 22-31
2. Glowniak J.V., Kilty J.E., Amara S.G., Hoffman B.J., and Turner F.E. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 34 (1993) 1140-1146
3. Linden D., Diehl R.R., and Berlit P. Sympathetic cardiovascular dysfunction in long-standing idiopathic Parkinson's disease. Clin Auton Res 7 (1997) 311-314
4. Wakabayashi K., and Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38 Suppl 2 (1997) 2-7
5. Goldstein D.S. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2 (2003) 669-676
6. Orimo S., Ozawa E., Nakade S., Sugimoto T., and Mizusawa H. (123)I-Metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67 (1999) 189-194
7. 123]I-meta-iodobenzyl guanidine in Parkinson's disease. Nucl Med Commun 19 (1998) 137-142
8. 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 40 (1999) 371-375
9. Suzuki M., Urashima M., Oka H., Hashimoto M., and Taira K. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease. NeuroReport 18 (2007) 1867-1870
10. Spiegel J., Hellwig D., Farmakis G., Jost W.H., Samnick S., Fassbender K., et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 22 (2007) 1004-1008
11. 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 243 (2006) 101-104
12. Orimo S., Amino T., Yokochi M., Kojo T., Uchihara T., Takahashi A., et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 20 (2005) 1350-1353
13. Orimo S., Oka T., Miura H., Tsuchiya K., Mori F., Wakabayashi K., et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73 (2002) 776-777
14. Gerlach M., Riederer P., Przuntek H., and Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208 (1991) 273-286
15. Tipton K.F., and Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61 (1993) 1191-1206
16. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
17. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80 (1983) 4546-4550
18. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405 (1987) 26-38
19. Sonsalla P.K., and Heikkila R.E. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 129 (1986) 339-345
20. Fuller R.W., Hahn R.A., Snoddy H.D., and Wikel J.H. Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 33 (1984) 2957-2960
21. Fuller R.W., Hemrick-Luecke S.K., and Robertson D.W. Comparison of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) effects on mouse heart norepinephrine. Biochem Pharmacol 37 (1988) 3343-3347
22. Wallace R.A., Boldry R., Schmittgen T., Miller D., and Uretsky N. Effect of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain & heart. Life Sci 35 (1984) 285-291
23. Hemrick-Luecke S.K., Mitch C.H., Quimby S.J., and Fuller R.W. Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine, an analog of MPTP, on mouse heart norepinephrine and brain catecholamines. Neurochem Int 23 (1993) 467-470
24. Takatsu H., Nishida H., Matsuo H., Watanabe S., Nagashima K., Wada H., et al. Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 41 (2000) 71-77
25. 125I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease. Nucl Med Commun 23 (2002) 161-166
26. 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism. Nucl Med Biol 33 (2006) 37-42
27. Amino T., Uchihara T., Tsunekawa H., Takahata K., Shimazu S., Mizusawa H., et al. Myocardial nerve fibers are preserved in MPTP-treated mice, despite cardiac sympathetic dysfunction. Neurosci Res 60 (2008) 314-318
28. Kiyono Y., Iida Y., Kawashima H., Ogawa M., Tamaki N., Nishimura H., et al. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 29 (2002) 999-1005
29. Kiyono Y., Iida Y., Kawashima H., Tamaki N., Nishimura H., and Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med 28 (2001) 894-899
30. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
31. Sundstrom E., Fredriksson A., and Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease. Brain Res 528 (1990) 181-188
32. Ricaurte G.A., Langston J.W., Delanney L.E., Irwin I., Peroutka S.J., and Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res 376 (1986) 117-124
33. Heikkila R.E., Sieber B.A., Manzino L., and Sonsalla P.K. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chem Neuropathol 10 (1989) 171-183
34. Marien M., Briley M., and Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol 236 (1993) 487-489
35. 123I]Meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med 42 (2003) 127-128
36. Amino T., Orimo S., Itoh Y., Takahashi A., Uchihara T., and Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 15 (2005) 29-34
37. Eisenhofer G., Esler M.D., Meredith I.T., Dart A., Cannon III R.O., Quyyumi A.A., et al. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation 85 (1992) 1775-1785
38. Algeri S., Ambrosio S., Garofalo P., and Gerli P. Peripheral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its main metabolite 1-methyl-4-phenylpyridinium ion (MPP+) in the rat. Eur J Pharmacol 141 (1987) 309-312